Skip to content
TrialScanner

NCT03679598

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Phase 2CompletedMREOCollaborator

Registry record

Lead sponsor
University of Alabama at Birmingham
Conditions
Alpha-1 Antitrypsin Deficiency (AATD); Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations; Emphysema or COPD
Primary completion
Nov 30, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03679598 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03679598: Alvelestat (MPH966) for the... | TrialScanner